

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: **2005-05-02** | Period of Report: **2005-04-26**

SEC Accession No. **0001079974-05-000152**

([HTML Version](#) on secdatabase.com)

FILER

IN VERITAS MEDICAL DIAGNOSTICS, INC.

CIK: **1142733** | IRS No.: **841579760** | State of Incorporation: **CO** | Fiscal Year End: **0731**

Type: **8-K** | Act: **34** | File No.: **000-49972** | Film No.: **05791528**

SIC: **3841** Surgical & medical instruments & apparatus

Mailing Address

*THE GREEN HOUSE
BEECHWOOD BUSINESS
PARK NORTH
INVERNESS - SCOTLAND L2
1V2 3BL*

Business Address

*THE GREEN HOUSE
BEECHWOOD BUSINESS
PARK NORTH
INVERNESS - SCOTLAND L2
1V2 3BL
011 44-1463-667-347*

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities and Exchange Act of 1934

Date of Report (Date of earliest event reported): April 26, 2005

IN VERITAS MEDICAL DIAGNOSTICS, INC.

(Exact name of registrant as specified in charter)

Colorado	000-49972	84-15719760
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

The Green House, Beechwood Business Park, North, Inverness, Scotland IV2 3BL

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: 011-44-1463-667347

Copies to:

Richard A. Friedman, Esq.
Sichenzia Ross Friedman Ference LLP
1065 Avenue of the Americas, 21st Floor
New York, New York 10018
(212) 930-9700
(212) 930-9725 (fax)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange

Act (17 CFR 240.14d-2(b))

/_/ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

On April 26, 2005, Bernard Turner resigned from his positions as Chief Financial Officer and as a director of In Veritas Medical Diagnostics, Inc. (the "Company"). In addition, David Barnes resigned as a director of the Company. There was no disagreement or dispute between Mr. Turner or Mr. Barnes and the Company which led to their resignations.

On April 26, 2005, Martin E. Thorp, 53 years old, was appointed as the Chief Financial Officer of the Company. From 2002 through 2005, Mr. Thorp had been involved in various entrepreneurial activities including, the establishment of Biz-Bud Ltd., a private company which provides outsourcing solutions for the small and mid-sized enterprises ("SMEs") across the entire business support spectrum; developing a consulting capability for SMEs; acting as a consultant to an international corporate finance and strategic advisory boutique; serving as strategic advisory non-executive board member of Grant Thornton; and serving in various short term consulting and interim management positions. From 1996 to 2002, Mr. Thorp served as Global Managing Partner, Corporate Finance for Arthur Andersen, London and New York. Mr. Thorp graduated with first class honors from the University of Kent at Canterbury (UK) in Accounting and Business Finance. Mr. Thorp is a Fellow of the Institute of Chartered Accountants in England and Wales and a member of the Securities Institute (in the UK).

Item 8.01 Other Events

We issued a press release on April 26, 2005, announcing Mr. Thorp as the new Chief Financial Officer, which is furnished as Exhibit 99.1 to this report.

Item 9.01 Financial Statements and Exhibits.

(a) Financial statements of business acquired.

Not applicable.

(b) Pro forma financial information.

Not applicable.

(c) Exhibits

Exhibit Number

Description

99.1

Press release dated April 26, 2005 announcing the
appointment of Martin Thorp as Chief Financial Officer

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IN VERITAS MEDICAL DIAGNOSTICS, INC.

Date: May 2, 2005

/s/ John Fuller

John Fuller

President and Chief Executive Officer

IVMD Names Chief Financial Officer

Inverness, Scotland, April 26, 2005 - In Veritas Medical Diagnostics, Inc. (OTCBB: IVME) today announced that Martin Thorp has joined the company as Chief Financial Officer.

John Fuller, President and CEO, made the announcement noting: "I am delighted Martin has agreed to join us. He brings a wealth of experience in fundraising and acquisitions as well as the operational processes involved in the American market. Martin will be actively looking for opportunities to grow our business."

Thorp noted, "IVMD represents a great opportunity to grow into a significant business and I am very excited at becoming a part of the company at this early stage. The portfolio of products creates significant opportunities for growth and I believe my experience can assist in providing added value to IVMD."

Thorp has a background in corporate finance and mergers and acquisitions, both in the US and UK. He had a long career with the former Arthur Andersen, serving as Global Managing Partner, Corporate Finance in both New York and London. Since 2002 he has been an independent consultant, including serving as a strategic advisory non-executive board member of Grant Thornton.

He attended the University of Kent at Canterbury and achieved a first class honors degree in accounting and business finance. He is a Fellow of the Institute of Chartered Accountants in England and Wales, and a member of the Securities Institute.

About In Veritas Medical Diagnostics

In Veritas Medical Diagnostics, Inc. consists of two wholly-owned subsidiaries based in the UK, IVMD (UK) Ltd. and Jopejo Ltd. IVMD (UK) is in the final stage of its first groundbreaking medical device for the multi-billion dollar cardio-vascular market. Other medical conditions being addressed by IVMD's patented technology include the diabetes market and other areas where imaging is essential. Although the Hall Effect, the basic phenomena behind much of IVMD's technology, has been known since 1875, it is only through recent developments in semi-conductor technology and computing power that scientists have been able to apply it to the measurement of the magnetic properties of bone and tissue - thereby enabling the Hall Effect to be considered in medical uses. The Hall Effect is a principle of physics discovered by E.H. Hall that is the measurable transverse voltage that occurs when an electric current flows through a conductor in a magnetic field. IVMD has a substantial portfolio of patents and patent applications relating to its technology. Jopejo Ltd. Is also in the late stages of developing new and technically superior monitoring devices that utilize signal processing for the late-term pregnancy market.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words "believe", "expects", "projects", "forecasts", "intends", "will", "anticipated", "could", or "may", and similar conditional expressions are intended to identify forward-looking statements within the meaning of the act and are subject to the safe harbor created by the act. Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements that involve a number of risks and uncertainties.

Contact: Bev Jedynak
 Martin E. Janis & Company, Inc.
 312-943-1100 ext. 12
 bjedynak@janispr.com